

42. A method for killing a cell expressing telomerase reverse transcriptase, comprising contacting the cell with the recombinant virus of claim 27.
43. The method for killing a cell according to claim 42, wherein the cell is a cancer cell.
44. The method for killing a cell according to claim 43, wherein the cancer is selected from the group consisting of lung cancer, pancreatic cancer, medulloblastoma, cervical carcinoma, and fibrosarcoma.
45. A method of treating a subject for a condition associated with increased expression of TERT in affected cells, comprising administering to the subject an effective amount of the recombinant virus according to claim 27.
46. The method of claim 45, wherein the condition is cancer.

REMARKS

The replacement drawings are filed to bring the drawings into compliance with formal drawing requirements. In PCT/US00/03104, the 8 pages of drawings comprised no Figure 4(B), and two sheets of Figure 4(C). In the replacement drawings, Figure 4(C) has been renumbered as Figure 4(B), and the duplicate sheet has been eliminated.

By way of this amendment, the specification has been revised to reflect the new numbering of the drawings. The drawing referred to as Figure 4(B) in PCT/US00/03104 is not necessary for understanding of the invention. Results for the cell lines A549, AsPC-1 and BxPC-3 are provided in Table 2 (page 42) as originally filed and as amended, and in the accompanying text.

The new claims are supported by claims 1-26 as originally filed in PCT/US00/03104.


Accordingly, no new matter is added to the disclosure as a result of entering these amendments.

The amendments are made to expedite prosecution of the application. No dedication to the public of any subject matter previously claimed or described in the disclosure is intended.

Applicants reserve the right to introduce claims to additional subject matter in this or any related application.

No fee is believed due with respect to the filing of this Preliminary Amendment. However, should the Patent Office determine that any relief is required for consideration of this paper, applicants hereby petition for such relief, and authorize the Assistant Commissioner to charge any fees due under 37 CFR §§ 1.16 and 1.17 (or credit any overpayment) to Deposit Account No. 07-1139, referencing the docket number indicated above.

Respectfully submitted,



J. Michael Schiff
Registration No. 40,253

GERON CORPORATION
230 Constitution Drive
Menlo Park, CA 94025
Telephone: (650) 473-7715
Fax: (650) 473-8654

July 11, 2000.